| Literature DB >> 34587966 |
Yu Yu1, Tian Lan2, Dandan Wang1, Wangsheng Fang3, Yu Tao1, Minghui Li1, Xiao Huang1, Wei Zhou4, Tao Wang4, Lingjuan Zhu4, Huihui Bao5,6, Xiaoshu Cheng7,8.
Abstract
BACKGROUND: Current studies support lipid ratios [the total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio; the triglyceride (TG)/HDL-C ratio; the low-density lipoprotein cholesterol (LDL -C)/HDL-C ratio; and non-HDL-C] as reliable indicators of cardiovascular disease, stroke, and diabetes. However, whether lipid ratios could serve as markers for hyperuricemia (HUA) remains unclear due to limited research. This study aimed to explore the association between lipid ratios and HUA in hypertensive patients.Entities:
Keywords: High-density lipoprotein cholesterol; Hypertension; Hyperuricemia; Lipid ratios; Rural China
Mesh:
Substances:
Year: 2021 PMID: 34587966 PMCID: PMC8482679 DOI: 10.1186/s12944-021-01556-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Characteristics of Study Population
| Variables* | Total ( | non-HUA ( | HUA ( | |
|---|---|---|---|---|
| Age, years | 63.81 ± 9.36 | 63.57 ± 8.98 | 64.10 ± 9.82 | < 0.001 |
| Male, % | 6716 (47.21) | 2624 (33.19) | 4092 (64.75) | < 0.001 |
| Current smoking, % | 3660 (25.73) | 1623 (20.53) | 2037 (32.24) | < 0.001 |
| Alcohol use, % | 3065 (21.55) | 1225 (15.50) | 1840 (29.12) | < 0.001 |
| Stroke | 983 (6.91) | 544 (6.88) | 439 (6.95) | 0.877 |
| CHD | 729 (5.12) | 364 (4.60) | 365 (5.78) | 0.002 |
| Diabetes mellitus | 2617 (18.39) | 1353 (17.11) | 1264 (20.00) | < 0.001 |
| Antihypertensive drugs | 9223 (64.84) | 4968 (62.85) | 4255 (67.34) | < 0.001 |
| Glucose-lowering drugs | 754 (5.30) | 417 (5.27) | 337 (5.33) | 0.877 |
| Lipid-lowering drugs | 506 (3.56) | 285 (3.60) | 221 (3.50) | 0.731 |
| BMI, kg/m2 | 23.61 ± 3.74 | 23.29 ± 3.82 | 24.01 ± 3.60 | < 0.001 |
| SBP, mmHg | 148.39 ± 17.86 | 149.30 ± 17.38 | 147.25 ± 18.38 | < 0.001 |
| DBP, mmHg | 88.93 ± 10.75 | 88.62 ± 10.39 | 89.31 ± 11.18 | < 0.001 |
| TC, mmol/L | 5.16 ± 1.12 | 5.11 ± 1.08 | 5.21 ± 1.16 | < 0.001 |
| TG, mmol/L | 1.81 ± 1.26 | 1.65 ± 1.06 | 2.00 ± 1.46 | < 0.001 |
| LDL-C, mmol/L | 2.98 ± 0.81 | 2.94 ± 0.79 | 3.03 ± 0.84 | < 0.001 |
| HDL-C, mmol/L | 1.57 ± 0.43 | 1.60 ± 0.43 | 1.53 ± 0.42 | < 0.001 |
| TC/HDL-C ratio | 3.44 ± 0.87 | 3.33 ± 0.81 | 3.57 ± 0.92 | < 0.001 |
| TG/HDL-C ratio | 1.32 ± 1.29 | 1.18 ± 1.06 | 1.51 ± 1.50 | < 0.001 |
| LDL-C/HDL-C ratio | 2.01 ± 0.66 | 1.94 ± 0.62 | 2.10 ± 0.69 | < 0.001 |
| non-HDL-C, mmol/L | 3.59 ± 1.00 | 3.51 ± 0.95 | 3.68 ± 1.05 | < 0.001 |
| Hcy, µmol/L | 17.96 ± 11.13 | 16.29 ± 9.29 | 20.06 ± 12.77 | < 0.001 |
| FBG, mmol/L | 6.18 ± 1.61 | 6.16 ± 1.71 | 6.21 ± 1.47 | 0.094 |
| eGFR, ml/min/1.73m2 | 88.18 ± 20.22 | 94.49 ± 16.18 | 80.28 ± 21.93 | < 0.001 |
Abbreviations: CHD, coronary heart disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; Hcy, homocysteine; FBG, fasting blood glucose; eGFR, estimated glomerular filtration rate
*Data are presented as mean ± standard deviation or median (interquartile range) and numbers (percentage) as appropriate
Note: The TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C ratios were calculated as TC, TG, and LDL-C divided by HDL-C, respectively. Non-HDL-C was calculated as HDL-C subtracted from TC.
Fig. 1The association between TC/HDL-C (A), TG/HDL-C (B), LDL-C/HDL-C ratio (C), or non-HDL-C (D) and HUA. Adjusted for age, sex, BMI, SBP, DBP, current smoking, alcohol use, eGFR, Hcy, diabetes mellitus, antihypertensive drugs, and lipid-lowering drugs
Odds ratios (95 % CI) for HUA according to continuous and tertiles of lipid ratios
| Crude model | Adjusted model | |||||
|---|---|---|---|---|---|---|
| Variables | N | Events, n (%) | OR (95 %CI) | OR (95 %CI) | ||
| 14,227 | 6320 (44.42 %) | 1.37 (1.32, 1.43) | < 0.001 | 1.35 (1.28, 1.41) | < 0.001 | |
| Tertiles of TC/HDL-C ratio | ||||||
| T1 (< 2.75) | 4,742 | 1795 (37.85 %) | Reference | Reference | ||
| T2 (2.75–4.12) | 4,742 | 2032 (42.85 %) | 1.23 (1.13, 1.34) | < 0.001 | 1.32 (1.20, 1.46) | < 0.001 |
| T3 (≥ 4.12) | 4,743 | 2493 (52.56 %) | 1.82 (1.68, 1.97) | < 0.001 | 1.78 (1.61, 1.97) | < 0.001 |
| < 0.001 | < 0.001 | |||||
| 14,227 | 6320 (44.42 %) | 1.26 (1.22, 1.30) | < 0.001 | 1.27 (1.23, 1.32) | < 0.001 | |
| Tertiles of TG/HDL-C ratio | ||||||
| T1 (< 0.62) | 4,740 | 1773 (37.41 %) | Reference | Reference | ||
| T2 (0.62–2.03) | 4,744 | 2002 (42.20 %) | 1.22 (1.13, 1.33) | < 0.001 | 1.30 (1.17, 1.43) | < 0.001 |
| T3 (≥ 2.03) | 4,743 | 2545 (53.66 %) | 1.94 (1.79, 2.10) | < 0.001 | 2.09 (1.88, 2.32) | < 0.001 |
| < 0.001 | < 0.001 | |||||
| 14,227 | 6320 (44.42 %) | 1.45 (1.38, 1.53) | < 0.001 | 1.40 (1.32, 1.50) | < 0.001 | |
| Tertiles of LDL/HDL-C ratio | ||||||
| T1 (< 1.49) | 4,741 | 1817 (38.33 %) | Reference | Reference | ||
| T2 (1.49–2.53) | 4,743 | 2040 (43.01 %) | 1.21 (1.12, 1.32) | < 0.001 | 1.31 (1.19, 1.45) | < 0.001 |
| T3 (≥ 2.53) | 4,743 | 2463 (51.93 %) | 1.74 (1.60, 1.89) | < 0.001 | 1.65 (1.49, 1.82) | < 0.001 |
| < 0.001 | < 0.001 | |||||
| 14,227 | 6320 (44.42 %) | 1.19 (1.15, 1.23) | < 0.001 | 1.33 (1.28, 1.39) | < 0.001 | |
| Tertiles of non-HDL-C | ||||||
| T1 (< 2.81) | 4,742 | 1933 (40.76 %) | Reference | Reference | ||
| T2 (2.81–4.36) | 4,732 | 2020 (42.69 %) | 1.08 (1.00, 1.17) | 0.0575 | 1.29 (1.17, 1.42) | < 0.001 |
| T3 (≥ 4.36) | 4,753 | 2367 (49.80 %) | 1.44 (1.33, 1.56) | < 0.001 | 1.89 (1.71, 2.09) | < 0.001 |
| < 0.001 | < 0.001 | |||||
Abbreviations: OR, odds ratio; CI, confidence interval; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol
Adjusted model: adjusted for age, sex, BMI, SBP, DBP, current smoking, alcohol use, eGFR, Hcy, diabetes mellitus, antihypertensive drugs, and lipid-lowering drugs